Literature DB >> 16210890

Cardiopulmonary exercise testing in Fabry disease.

Gregory Bierer1, Nader Kamangar, David Balfe, William R Wilcox, Zab Mosenifar.   

Abstract

BACKGROUND: Fabry disease is a rare X-linked disorder that results from a deficiency in a lysosomal enzyme known as alpha-galactosidase A, with accumulation of globotriaosylceramide (Gl3). Early manifestations include angiokeratomas, acroparesthesias, and hypohidrosis and may progress to renal failure, cardiac dysfunction, and stroke. Patients exhibit decreased exercise tolerance and often complain of fatigue.
OBJECTIVE: Our study evaluates the cardiopulmonary characteristics in a cohort of Fabry disease patients at rest and during exercise.
METHODS: Thirty-nine patients with a diagnosis of Fabry disease underwent a health screening history and physical examination, an electrocardiogram, an echocardiogram, pulmonary function testing (spirometry), and a non-invasive cardiopulmonary exercise test. A control group was selected for comparison.
RESULTS: Eighteen of the 39 Fabry patients (46%) exhibited a significant decrease in diastolic blood pressure (DBP) during exercise. The average decrease in DBP was 10 mm Hg. The maximum drop in DBP was 44 mm Hg. The drop in DBP was evident in 9 of the 24 female patients (38%). None of the control patients had a significant drop in DBP during exercise.
CONCLUSIONS: Our finding of a significant decrease in DBP in patients with Fabry disease may explain deficits in exercise tolerance. It is notable that this abnormality is manifested in female patients, even though they are typically not as severely affected as males. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 16210890     DOI: 10.1159/000087675

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  10 in total

1.  Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease.

Authors:  Gregory Bierer; David Balfe; William R Wilcox; Zab Mosenifar
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

2.  Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.

Authors:  R Y Wang; J T Abe; A H Cohen; W R Wilcox
Journal:  J Inherit Metab Dis       Date:  2008-10-21       Impact factor: 4.982

Review 3.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

4.  Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study.

Authors:  Daniel P Franzen; Albina Nowak; Sarah R Haile; Dominique Mottet; Marco Bonani; Olivier Dormond; Malcolm Kohler; Pierre A Krayenbuehl; Frederic Barbey
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

5.  Serial Analysis of Cardiopulmonary Fitness and Echocardiography in Patients with Fabry Disease Undergoing Enzyme Replacement Therapy.

Authors:  Sheng-Hui Tuan; Pao-Chin Chiu; I-Hsiu Liou; Wen-Hsien Lu; Hung-Ya Huang; Shin-Yi Wu; Guan-Bo Chen; Ko-Long Lin
Journal:  J Rehabil Med Clin Commun       Date:  2020-02-27

6.  A single lung transplant in a patient with fabry disease: causality or far-fetched? A case report.

Authors:  Martina Gaggl; Renate Kain; Peter Jaksch; Dominik Haider; Gerald Mundigler; Till Voigtländer; Raute Sunder-Plassmann; Paulus Rommer; Walter Klepetko; Gere Sunder-Plassmann
Journal:  Case Rep Transplant       Date:  2013-04-07

7.  Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.

Authors:  Aurelie Nguyen Dinh Cat; Brigitte Escoubet; Vincent Agrapart; Violaine Griol-Charhbili; Trenton Schoeb; Wenguang Feng; Edgar Jaimes; David G Warnock; Frederic Jaisser
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

Review 8.  Fabry disease, respiratory symptoms, and airway limitation - a systematic review.

Authors:  Camilla Kara Svensson; Ulla Feldt-Rasmussen; Vibeke Backer
Journal:  Eur Clin Respir J       Date:  2015-06-26

9.  Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy.

Authors:  Daniel Franzen; Sarah R Haile; David C Kasper; Thomas P Mechtler; Andreas J Flammer; Pierre A Krayenbühl; Albina Nowak
Journal:  BMJ Open Respir Res       Date:  2018-04-21

Review 10.  Anderson-Fabry disease in heart failure.

Authors:  M M Akhtar; P M Elliott
Journal:  Biophys Rev       Date:  2018-06-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.